Volume 157, Issue 2 p. 431-436
CLINICAL ARTICLE

Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers—an Israeli matched-pair study

Tamar Perri

Tamar Perri

Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel

Department of Gynecologic Oncology, Hadassah Medical Center, Jerusalem, Israel

Search for more papers by this author
Gabriel Levin

Corresponding Author

Gabriel Levin

Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel

Department of Gynecologic Oncology, Hadassah Medical Center, Jerusalem, Israel

Correspondence

Gabriel Levin, Department of Obstetrics and Gynecology, Hadassah-Hebrew University Medical Center, POB 12000, Jerusalem, 91120, Israel.

Email: [email protected]

Search for more papers by this author
Shani Naor-Revel

Shani Naor-Revel

Department of Gynecologic Oncology, Sheba Medical Center, Tel Hashomer, Israel

Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel

Search for more papers by this author
Perry Eliassi-Revivo

Perry Eliassi-Revivo

Department of Gynecologic Oncology, Sheba Medical Center, Tel Hashomer, Israel

Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel

Search for more papers by this author
Dror Lifshitz

Dror Lifshitz

Department of Gynecologic Oncology, Sheba Medical Center, Tel Hashomer, Israel

Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel

Search for more papers by this author
Eitan Friedman

Eitan Friedman

Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel

Susanne Levy-Gertner Oncogenetics Unit, Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel

Search for more papers by this author
Jacob Korach

Jacob Korach

Department of Gynecologic Oncology, Sheba Medical Center, Tel Hashomer, Israel

Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel

Search for more papers by this author
First published: 29 July 2021
Citations: 6

Tamar Perri and Gabriel Levin contributed equally to this article.

Abstract

Objective

To study the association of risk-reducing bilateral salpingo-oophorectomy (RRBSO) and breast cancer risk among BRCA pathogenic sequence variants (PSV).

Methods

Jewish Israeli BRCA carriers who underwent RRBSO were matched with those who did not—by the mutated gene and year of birth (±1 year). Breast cancer rates were compared.

Results

Overall, 127 pairs met the inclusion criteria, 79 (60.6%) pairs harbored BRCA1 PSV and 50 (39.4%) pairs harbored BRCA2 PSV. Median follow up was 8.7 years (interquartile range 4.6–16.1 years). Breast cancer rate for all BRCA carriers combined was not affected by RRBSO (RRBSO 21 [16.5%] versus no RRBSO 31 [24.4%], hazard ratio [HR] for breast cancer 0.61, 95% confidence interval [CI] 0.33–1.14, P = 0.127). No association between RRBSO and breast cancer incidence was noted among BRCA1 PSV carriers. In BRCA2 PSV carriers, RRBSO was associated with a decreased overall breast cancer incidence (HR 0.20, 95% CI 0.44–0.91, P = 0.038), as well as after 5, 10, 15, and 20 years. Hormone replacement therapy was used by 62 PSV carriers, 52 in the RRBSO group and 10 in the no-RRBSO group and did not affect breast cancer risk (P = 0.463).

Conclusion

RRBSO is associated with breast cancer risk reduction in Jewish Israeli BRCA2 PSV carriers.

Risk-reducing bilateral salpingo-oophorectomy was associated with breast cancer risk reduction in Jewish Israeli BRCA2 pathogenic sequence variant carriers.

CONFLICTS OF INTEREST

The authors have no conflicts of interest.